Comparative Pharmacology
Head-to-head clinical analysis: EDOXABAN versus HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDOXABAN versus HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
EDOXABAN vs HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective, direct, reversible inhibitor of factor Xa, blocking the conversion of prothrombin to thrombin, thereby reducing thrombin generation and thrombus formation.
Heparin binds to antithrombin III, accelerating its inhibition of thrombin (factor IIa) and factor Xa, thereby preventing fibrin clot formation.
60 mg orally once daily
Initial IV bolus of 80 units/kg, followed by continuous IV infusion at 18 units/kg/hour; subsequent dosing based on aPTT. For DVT/PE: initial bolus of 5,000 units or 80 units/kg, then 1,000-2,000 units/hour continuously.
None Documented
None Documented
Terminal elimination half-life is 10-14 hours. In patients with creatinine clearance 15-50 mL/min, half-life is prolonged to approximately 17-20 hours.
30–90 minutes (mean 1.5 h) for therapeutic doses; dose-dependent and saturable elimination: increases with dose (e.g., 100 U/kg: ~56 min; 400 U/kg: ~152 min). At lower doses, half-life may be shorter due to rapid clearance.
Renal excretion accounts for approximately 50% of the administered dose. Fecal excretion accounts for approximately 40%. Biliary excretion is minimal.
Renal: minimal intact heparin; primarily hepatic degradation via desulfation and depolymerization into inactive metabolites (uroheparin) excreted renally. Biliary/fecal: negligible (<1%).
Category C
Category A/B
Anticoagulant
Anticoagulant